V
Verena Haselmann
Researcher at Heidelberg University
Publications - 31
Citations - 453
Verena Haselmann is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 19 publications receiving 281 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 antibody testing-questions to be asked.
Mustafa Özcürümez,Andreas Ambrosch,Oliver Frey,Verena Haselmann,Stefan Holdenrieder,Michael Kiehntopf,Michael Neumaier,Michael Walter,Michael Walter,Folker Wenzel,Roman Wölfel,Harald Renz +11 more
TL;DR: The recently established COVID-19 Task Force of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL) addresses issues based on the currently available datasets in this rapidly moving field of antibody testing.
Journal ArticleDOI
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β-catenin by sequestering TCF4 to the nuclear membrane
Anke Loregger,Martina Grandl,Raquel Mejías-Luque,Michael Allgäuer,Kathrin Degenhart,Verena Haselmann,Christina Oikonomou,Pantelis Hatzis,Klaus-Peter Janssen,Ulrich Nitsche,Dietmar Gradl,Olaf Van Den Broek,Olivier Destrée,Kurt Ulm,Michael Neumaier,Behnam Kalali,Andreas Jung,Ignacio Varela,Roland M. Schmid,Roland Rad,Dirk H. Busch,Markus Gerhard +21 more
TL;DR: These findings indicate that RNF43 inhibits the Wnt pathway downstream of oncogenic mutations that activate the pathway, and may be useful to treat cancers arising from aberrant activation of the WNT pathway.
Journal ArticleDOI
Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA).
Verena Haselmann,Parviz Ahmad-Nejad,Wolf J. Geilenkeuser,Angelika Duda,Merle Gabor,Romy Eichner,Simon Patton,Michael Neumaier +7 more
TL;DR: This pilot EQA scheme illustrates the current variability in multiple phases of cfDNA processing and analysis of ctDNA resulting in an overall error rate of 6.09%.
Journal ArticleDOI
Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
Verena Haselmann,Christoffer Gebhardt,Christoffer Gebhardt,Ingrid Brechtel,Angelika Duda,Claudia Czerwinski,Antje Sucker,Tim Holland-Letz,Jochen Utikal,Jochen Utikal,Dirk Schadendorf,Michael Neumaier +11 more
TL;DR: Blood-based BRAF testing correlates with the clinical course, even for early-stage patients, and may be used to predict response to treatment, recurrence, and resistance before radioimaging under BRAFi therapy, thereby enabling considerable improvements in patient treatment.
Journal ArticleDOI
Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples.
Verena Haselmann,Maximilian Kittel,Catharina Gerhards,Margot Thiaucourt,Romy Eichner,Victor Costina,Michael Neumaier +6 more
TL;DR: There is an urgent need for test harmonization and establishment of quality standards for an appropriate use of COVID-19 serological tests in serum and plasma samples.